Condition
Transfusional Hemosiderosis
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
75%
3 of 4 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (3)
P 4 (1)
Trial Status
Completed4
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00845871Phase 4CompletedPrimary
Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
NCT00631163Phase 2Completed
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
NCT01927913Phase 2Withdrawn
Treatment of Iron Overload Requiring Chelation Therapy
NCT01394029CompletedPrimary
Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
NCT00600938Phase 2Completed
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
Showing all 5 trials